Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03965845 · ClinicalTrials.gov registry record · Phase 1
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
A Phase 1 study, sponsored by Calithera Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT03965845 is a Phase 1 study that has completed, run by Calithera Biosciences. The registered enrollment target is 53 participants.
The verdict
NCT03965845, a Phase 1 study, has completed, sponsored by Calithera Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor telaglenestat (CB-839) with the CDK4/6 Inhibitor, palbociclib in participants with advanced/metastatic solid tumors.
Interventions
- DRUG Telaglenestat (CB-839)
- DRUG Palbociclib Oral Capsule or Tablet [Ibrance]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2019-06-25 |
| Est. Completion | 2021-09-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03965845
The ClinicalTrials.gov registry entry for NCT03965845 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calithera Biosciences, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Telaglenestat (CB-839) is the first listed.
NCT03965845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03965845 about?
NCT03965845 is a clinical study titled "A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors". This is a Phase 1b/2 study to determine the recommended phase 2 dose (RP2D), safety and tolerability, pharmacokinetics (PK) and clinical activity of the glutaminase inhibitor telaglenestat (CB-839) with the CDK4/6 Inhibitor, palbociclib in participants with advanced/metastatic solid tumors.
What is the current status of trial NCT03965845?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2019-06-25. Estimated completion is 2021-09-24.
What interventions are being tested in trial NCT03965845?
The interventions under investigation include: Telaglenestat (CB-839) (DRUG), Palbociclib Oral Capsule or Tablet [Ibrance] (DRUG).
Who is sponsoring clinical trial NCT03965845?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.